Role of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Anemia in CKD: Key Considerations for Pharmacists

Educational Objectives:,At the completion of this activity, participants will be able to:,• Explain the prevalence, pathophysiology, and complications of anemia in chronic kidney disease (CKD),• Identify the current challenges in standards of care with treating anemia in CKD,• Examine the role of hypoxia-inducible factor prolyl hydroxylase inhibitors and novel therapies under investigation in this drug class,• Illustrate the role of the pharmacist and evidence-based best practices to develop strategies that effectively treat anemia in patients with CKD